Is Leronlimab too good to be true?

And the answer, for this poster to that question is a loud yes it is! And it get worse when new investors realize that the company's CEO actually treats its retail shareholders like adults and keeps them informed of the company's trials and tribulations in its efforts to get FDA approvals for the unbelievable number of indications that are being applied for approvals. I wouldn't be surprised given the number of indications that the company is working that insiders at that FDA might be asking the same question "Is this too good to be true"

But new investors should be very careful and not ask such sensitive questions as they may result in the release of accumulated bile within some old investors.
That would be most unfortunate as purchases by the same new investors have certainly helped blunt the effect of recent short attacks on share prices.
No harm meant!